Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...